What are Mission Vision & Core Values of Daiichi Sankyo Company?

How does Daiichi Sankyo define its purpose today?

What drives Daiichi Sankyo is a focused commitment to transform scientific innovation into accessible therapies, especially in oncology. Their strategy aligns R&D, partnerships, and capital allocation to accelerate patient-centric breakthroughs.

Daiichi Sankyo’s mission emphasizes creating novel medicines to save and enhance lives; its vision targets leadership in oncology innovation supported by multi-billion R&D investment and a global team of over 17,000. Core values center on integrity, patient focus, collaboration, and scientific excellence — guiding decisions from pipeline prioritization to market access. Read more via Daiichi Sankyo Porter's Five Forces Analysis

The mission emphasizes patient-centric innovation, targeting high unmet needs in oncology and cardiovascular-renal disease, and delivering global impact via proprietary DXd ADC technology and expanded access to life-extending therapies.

Target Patients

Focus on patients with refractory cancers and rare cardiometabolic conditions, prioritizing therapies where unmet need is highest.

Innovative Platform

DXd antibody-drug conjugate platform underpins pipeline and commercial success, notably expanding indications for Enhertu globally.

Global Footprint

Operations span the United States, Europe and emerging markets to maximize patient access and commercial reach.

Value Proposition

Delivering life‑extending therapies through scientific innovation rather than sole profit focus, aligning social contribution with growth.

Evidence & Impact

Clinical expansion of Enhertu and global approvals illustrate measurable patient benefit and revenue contribution to R&D-led growth.

Corporate Philosophy

Emphasizes scientific excellence, ethical responsibility and long‑term sustainability as core drivers of decisions and investments.

The mission links to a clear vision and core values: patient-centric innovation, scientific rigor, global access, and social contribution—aligning Daiichi Sankyo mission statement, Daiichi Sankyo vision and Daiichi Sankyo core values with measurable clinical and commercial outcomes. See a Brief History of Daiichi Sankyo for context: Brief History of Daiichi Sankyo

Complete Daiichi Sankyo Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Daiichi Sankyo’s vision is to become an Innovative Global Healthcare Company by 2030, leading the ADC revolution and making oncology >60% of revenue with at least seven blockbusters by decade-end.

Global oncology leadership

Focus on antibody-drug conjugates (ADCs) to disrupt established oncology markets and expand global reach.

Financial momentum

FY2024 revenue ~1.75 trillion JPY, driven by a 25% YoY rise in oncology sales.

Ambitious 2030 milestones

Target: oncology >60% of total revenue and seven or more blockbuster products by 2030.

Mission alignment

Mission emphasizes patient-first innovation, scientific rigor, and global access to therapies.

Core values

Values center on integrity, scientific excellence, collaboration, and patient focus across operations.

Strategic focus

Prioritizes R&D investment, partnerships, and scalable manufacturing to sustain competitive advantage.

Daiichi Sankyo mission statement and corporate philosophy emphasize patient-centric innovation, scientific integrity, and global impact; see Target Market of Daiichi Sankyo for related analysis.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Daiichi Sankyo's core values guide decision-making and culture, shaping research priorities and stakeholder commitments. These principles—Innovation, Integrity, and Accountability—drive the company's mission and long-term vision across R&D, ethics, and operational performance.

Innovation

Innovation fuels a high-R&D model, with R&D investment around 23–25% of annual revenue and a leading DXd ADC platform producing candidates such as Dato‑DXd.

Integrity

Integrity mandates ethical research and transparent clinical reporting, adherence to IFPMA standards, and patient-focused pricing and data practices.

Accountability

Accountability means delivering on the FY2021–FY2025 business plan targets, maintaining supply stability, and a progressive dividend policy for shareholders.

Collaboration

Collaboration across global teams and partners accelerates development and commercialization, aligning corporate philosophy with patient outcomes and strategic growth.

Explore how the Daiichi Sankyo mission statement and vision shape strategic decisions and growth; read the next chapter on how mission and vision influence strategy: Growth Strategy of Daiichi Sankyo

Daiichi Sankyo Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Mission and vision shape strategic choices by directing R&D priorities, partnerships, and market investments; they determine which therapeutic areas receive capital and talent. These statements provide a decision-making framework that aligns operations, M&A, and global expansion with long-term value creation.

Mission, Vision & Core Values — Snapshot

The company's mission and vision guide its shift to a specialty-led biopharma focused on oncology and rare diseases.

• Mission: To contribute to the enrichment of quality of life by delivering innovative pharmaceuticals that address diverse medical needs.
• Vision: To become a global leader in specialty therapeutics, particularly oncology, through scientific innovation and strategic collaborations.
• Core values: Integrity, patient-first mindset, scientific excellence, collaboration, and long-term value creation.
• Strategic outcome: Prioritization of specialty pipelines and global partnerships to scale commercialization and R&D impact.

Strategic Partnerships

The vision drove the multi-billion collaboration with AstraZeneca to accelerate oncology growth while sharing commercial reach and R&D risk.

U.S. Market Focus

The mission to meet diverse medical needs led to increased investment in the U.S., now the company’s primary growth engine.

Leadership & Culture

CEO Sunao Manabe reinforces 'One DS' to break down silos and align departments with the 2030 Vision and 'Value Creators' model.

Financial Signal

As of mid-2025 the company’s Market Capitalization exceeded 10 trillion JPY, reflecting investor confidence in its strategic direction.

Performance Metrics

Long-term planning ranks investments by potential to enhance patient value and sustainable returns rather than short-term EPS gains.

Where to find more

See a detailed look at the company’s revenue model and strategic drivers in this article: Revenue Streams & Business Model of Daiichi Sankyo

Explore how these guiding statements translate into measurable changes in the next chapter on Core Improvements to Company's Mission and Vision; read on to see prioritized initiatives and alignment metrics.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE

Four focused improvements can sharpen Daiichi Sankyo's mission, vision and core values to reflect 2025 realities in digital health, sustainability and global access. These changes align the company’s purpose with measurable targets and investor expectations.

Embed Data-Driven Healthcare into the Vision

Revise the Daiichi Sankyo vision to explicitly state leadership in AI-enabled drug discovery and real-world evidence, positioning the company as a global data-driven healthcare innovator to match 2025 industry trends where AI shortens drug discovery timelines by up to 30%.

Elevate Global Health Equity in the Mission

Add a clear commitment to access to medicine for low-and-middle-income countries, framing the Daiichi Sankyo mission statement around measurable coverage goals and aligning with ESG metrics sought by investors.

Integrate Environmental Sustainability Targets

Introduce explicit carbon-reduction and circularity targets into the corporate philosophy, such as a pathway to net-zero by 2050 and interim 40% emissions reduction by 2035, bringing the Purpose of Daiichi Sankyo in line with peer commitments.

Clarify Core Values Around Digital Ethics and Value-Based Care

Expand the list of Daiichi Sankyo core values to include digital ethics, data governance and a commitment to value-based care, ensuring employees and stakeholders understand what drives Daiichi Sankyo in a healthcare landscape focused on outcomes and equity.

Improvements While robust, Daiichi Sankyo’s mission and vision could be strengthened by incorporating more explicit language regarding digital transformation and environmental sustainability. Compared to peers like Novartis or Sanofi, who have integrated 'Data Science' and 'Carbon Neutrality' directly into their primary strategic pillars, Daiichi Sankyo’s statements remain heavily focused on the physical product (pharmaceuticals). A suggestion for refinement would be to evolve the vision to: 'To be a Global Leader in Data-Driven Healthcare and Oncology Innovation.' This would better align with the 2025 industry trend of using Artificial Intelligence (AI) for drug discovery and real-world evidence (RWE) for market access.

Additionally, as global healthcare shifts toward 'Value-Based Care,' the mission could more explicitly address the 'access to medicine' challenge in low-and-middle-income countries. While the company has programs in place, elevating 'Global Health Equity' to a core mission component would resonate more strongly with ESG-focused investors and international regulatory bodies. These adjustments represent growth opportunities to ensure the company remains relevant in a future where medicine is as much about data and delivery as it is about biology. Read more on ownership context in Owners & Shareholders of Daiichi Sankyo